Exchange: NASDAQ·Updated 04:30 PM EDT
News
all
press releases
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Zacks
QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.
Stocktwits
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?
uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure (NASDAQ:QURE) sharesread more...
Benzinga
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
Zacks
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Zacks
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
Zacks

Advertisement|Remove ads.